Skip to main content

Table 1 Trial Flowchart and Schedule of Visits

From: Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

Assessment

Study treatment

Follow up

Visit No.a

1

2

3

4

5

6

7

8

9

10

WEEKS

Screening

Baseline

13

26

39

52

65

78

91

104

Registration Form

X

         

Demographics

X

         

Eligibility checks b

X

         

Medical History

X

         

Physical Examination

 

X

 

X

 

X

 

X

 

X

Disease Activity Assessments

 

X

X

X

X

X

X

X

X

X

X-rays of hands & feet c

Xc

         

Ultrasonography of symptomatic joints and limited joint set d

 

Xd

 

Xd

 

Xd

 

Xd

 

Xd

ACR/EULAR remission

 

X

X

X

X

X

X

X

X

X

IMP supply for weekly SC dosing e

 

X

X

X

X

     

Treatment Log (IMP)

  

X

X

X

X

    

ESR & CRP f

X

 

X

X

X

X

X

X

X

X

Routine Bloods (Haem & Biochem) g n

Xg

 

X

X

X

X

Xn

Xn

Xn

Xn

Screening Bloods (HIV, Hep B& C, TB) c

Xc

         

Chest X-ray c

Xc

         

Lifestyle Factors Questionnaire

 

X

 

X

 

X

 

X

 

X

Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire h

 

Xh

   

Xh

    

Health Assessment Questionnaire (HAQ)

 

X

X

X

X

X

X

X

X

X

Modified Illness Perception Questionnaire (IPQ-R)

 

X

 

X

 

X

 

X

 

X

Euro-Quality of Life Questionnaire (EQ-5D)

 

X

 

X

 

X

 

X

 

X

Hospital Anxiety and Depression Scale (HADs)

 

X

 

X

 

X

   

X

Functional Assessment Of Chronic Illness Therapy-Fatigue Questionnaire (FACIT-F)

 

X

 

X

 

X

 

X

 

X

RA Work Instability Scale (RA-WIS)

 

X

 

X

 

X

 

X

 

X

Perceptions of Trial Participation Questionnaire i

Xi

         

Concomitant Medication

 

X

X

X

X

X

X

X

X

X

Adverse Events

 

X

X

X

X

X

X

X

X

X

Compliance checks j

  

X

X

X

X

    

Status Form

  

X

X

X

X

X

X

X

X

Withdrawal Form k

  

Xk

Xk

Xk

Xk

Xk

Xk

Xk

Xk

Blood/Urine for biomarkers l

 

X

X

X

X

X

X

X

X

X

  1. aFlexibility of scheduled visits will be allowed of +/- 2 weeks either side of visit
  2. bEligibility criteria
  3. cThese tests can be used if taken up to 12 weeks before screening
  4. dUltrasonography must be done before treatment is initiated at baseline visit and within 2 weeks either side of the scheduled 6, 12, 18 and 24 month Visit
  5. eThree months worth of IMP will be supplied for weekly subcutaneous dosing. Missed doses are only allowed if within ± 3 day window
  6. fThese assessments will not be necessary if the baseline visit is scheduled within two weeks of the screening visit
  7. gThese tests may be undertaken as part of routine assessments
  8. hSPARRA questionnaire will be given to participants to be completed in their own time after the study visit, to be returned to the local study team by post
  9. iPotential participants, including those that do not wish to participate in the APIPPRA study, will complete the Perceptions of Trial Participation Questionnaire following written consent
  10. jMonthly telephone calls will also be used to address compliance during IMP treatment period
  11. kAs required
  12. lSee Table 2, for schedule of sampling for exploratory biomarkers
  13. mSubjects will be randomised following baseline clinical assessments, ultrasonography and blood/urine samples
  14. nRoutine bloods beyond the 12 month study visit will be taken only if clinically indicated, and left to the discretion of the supervising physician